Articles By Jack Cush, MD
RheumNow Podcast – New World Order (3.27.20)
Dr. Jack Cush reviews the news and COVID developments from this past week.
Read Article
ACR Infusion Guidance During COVID-19 Crisis
The American College of Rheumatology (ACR) has published a guidance document on infusions and office based therapies.
Read Article
Staying Abreast of COVID-19
Dealing with unknowns is both difficult and frustrating, as the answer is often not within our reach. The current pandemic has created a tidal wave of unknowns, scaring patients and putting physicians in a difficult spot.
Read Article
RheumNow Podcast- COVID Siege (3.20.20)
Dr. Jack Cush reviews the past week of COVID-19 news and advances.
Read Article
COVID-19 Rheumatology News
With the COVID-19 pandemic dynamically changing, we have provided several news items germane to the Rheumatologist.
Read Article
Rheumatic Disease Drugs and COVID-19
We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most severely affected should they become infected with this virus. This has led to a great deal of uncertainty by patients and providers about how rheumatic diseases and their treatments need to be specifically addressed.
Read Article
RheumNow Podcast- Corona Increases RA Risk (3.13.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still's disease (AOSD) based on whether they received early or delayed treatment with anakinra (ANK). A total of 141 AOSD patients were retrospectively studied.
Read Article
Switching Biologics in JIA
While there are numerous agents approved for use in juvenile idiopathic arthritis, little is know about actual use biological disease-modifying antirheumatic drug (DMARD) use or switching in the biologic era. A cohort comparison study has shown that after an unsuccessful trial of a first biologic, changing to a second TNFi is as effective as switching to a non-TNFi biologic.
Read Article
